Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 1997

View Archived Issues

New alinidine analogues described

Ansan announces merger with Discovery Laboratories and licensing agreement with Titan

Garlic suggested to merit further evaluation for H. pylori infections

Cortecs and Astra promotion agreement for Helisal One Step

Positive results reported for MRSA test

NPY antagonists developed at Thomae

Amgen: Q2 1997 highlights

Pierre Fabre prepares compounds for hypercholesterolemia/atherosclerosis

Asta prepares and evaluates targeted cytotoxic anthracycline analogues

Phosphodiesterase inhibitors from Schering-Plough

Drug interactions and clinical efficacy of pazufloxacin/pazufloxacin mesilate

HSR-903: antichlamydial activity and drug interactions

Clinafloxacin vs. imipenem for empiric therapy of febrile granulocytopenic patients

DU-6859a: dose-finding study in UTI

FDA grants raloxifene NDA priority review status

Genetic and molecular pathogenesis of IDDM

More light shed on leptin and leptin receptors

Roberts seeks approval to begin clinical studies of gastrointestinal drug

Antibacterial activity and clinical efficacy of grepafloxacin reported

Quinolones remain at the forefront of antiinfective therapy

DynaGen expands ImmuDyn development

FDA clears potent pain reliever without opioid side effects from Wyeth-Ayerst

Potent, orally active azole antifungal from Bayer

Nicotine Inhaler launched in The Netherlands

New bactericidal antiseptic from Otsuka

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.